Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
FAIL · Does not pass the screen
203.77 USD
At the last full screen 2026-09-11
Screened 2026-09-11 · the tape above runs as of 17:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its accumulation label.
Revolution Medicines Inc holds its Accumulation at $203.77. Elevated stress, defensive posture warranted, held for 16 days.
As held on the ledger · 2026-09-11
Phase
Accumulation
Quantitative state
Elevated stress, defensive posture warranted, held for 16 days
Price at the screen
$203.77
Valuation
N/A trailing · -34.23 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.41
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
6.74%
Below 33%
Interest-bearing debt is just 6.7% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
69.74%
Below 33%
Interest-bearing cash and securities are 69.7% of assets, above the one-third limit.
Fail
Receivables
16.30%
Below 49%
Money owed to the company is 16.3% of assets, under the 49% limit.
Pass
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-11 screen. The gold marker is the market price at the same screen. A 22.4% margin of safety to the base estimate.
Third-party analyst targets: 20 covering, consensus Strong Buy. The average target sits +22% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-11 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Cancer Drug Hopes Clash With Heavy Losses
A firm chasing RAS driven tumours sounds like the future of oncology until you check the books. Revolution Medicines sits at a price that already prices in success yet still posts zero profit margin and a negative seventy seven per cent return on equity. With a narrow moat and an opportunity rating of none we simply pass.
The forward multiple of minus thirty two point five times reflects deep losses that will continue for years. Twenty two analysts may like the pipeline but our screen flags the gap between clinical promise and any path to cash. Ethical clearance does not offset the financial reality.
Risks centre on binary trial outcomes and repeated cash raises that dilute holders. A ten per cent margin to fair value offers little protection when earnings remain negative. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
RVMD trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-12Markdown · changed$203.77+3.0%Entry 5
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 3.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 74% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 243%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (21 analysts) rates it strong buy, with a mean price target of $187.
2026-08-12Markup$197.81+28.6%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 28.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 74% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 243%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (21 analysts) rates it strong buy, with a mean price target of $187.
2026-07-18Markup$153.87+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 74% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 243%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (21 analysts) rates it strong buy, with a mean price target of $187.
2026-07-03Markup$153.87+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markup$153.87Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
